PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6200680

[Antigen indication using the passive hemagglutination test].

V A Shamardin·B V Karal'nik·V I Zhiglov·N Zh Zhanuzakov
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

AntigensAntigens, BacterialEscherichia coliHemagglutination TestsHumansSalmonellaJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V A Shamardin, B V Karal'nik, V I Zhiglov, N Zh Zhanuzakov. 1984. [Antigen indication using the passive hemagglutination test].. https://pubmed.ncbi.nlm.nih.gov/6200680/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

The detection of antigen-induced IFNgamma secretion at the single cell level can be used to identify and enumerate antigen-reactive T cells from peripheral blood. This study was performed to analyze the suitability of T cell enumeration by flow cytometry in comparison with the ELISPOT assay. Peripheral blood mononuclear cell (PBMC) samples from six HLA-A2+ healthy subjects were analysed for the frequency of influenza-reactive CD8+ T cells by flow cytometry detecting either intracellular IFNgamma (IC-FC) or secreted IFNgamma (S-FC). All samples were also analysed by IFNgamma ELISPOT assay. The frequency of influenza peptide-reactive T cells determined by IC-FC was 0.01 to 0.34% of CD8+ T cells and by ELISPOT assay 0.02 to 0.23% of CD8+ T cells (n=6 subjects) with a high inter-assay reproducibility and a close correlation between the assays (r=0.77, P<0.001). Little or no IFNgamma production was observed in unstimulated PBMC samples using either the IC-FC or the ELISPOT assay. In contrast, using S-FC large numbers of IFNgamma-secreting CD8+ T cells (0.37% to 5.55%, n=6 subjects) were detected in unstimulated PBMC. The frequency of influenza-reactive CD8+ T cells (0.57-5.19%, n=6 subjects) determined by S-FC did not correlate with the values from the IC-FC or ELISPOT assays. This comparative study shows the suitability of the determination of frequencies of antigen reactive T cells in PBMC by IC-FC. The advantage of IC-FC is the possibility to phenotype simultaneously antigen-reactive T cells.

Antigens↗
PubMed2001

Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.

Although renal cell carcinoma has been shown to respond to immunotherapy, renal cell carcinoma-specific rejection antigens and their corresponding CTL epitopes have rarely been described. The use of dendritic cells (DCs) transfected with mRNA isolated from tumor cells may allow specific immunotherapy even in cancers for which potent rejection antigens have not been identified. Here we show that DCs transfected with RNA isolated from renal cancer tissue are remarkably effective in stimulating tumor-specific T-cell response in vitro but do not cross-react with normal tissue antigens including antigens expressed by renal parenchyma. In contrast, the tumor-specific CTLs lysed allogeneic tumor but not allogeneic normal tissue targets, suggesting the presence of shared albeit unidentified antigens among renal carcinomas. CTL responses against telomerase reverse transcriptase (TERT) accounted in part for the reactivities against allogeneic tumors because renal tumor RNA-transfected DCs stimulated polyclonal CTL responses, which encompassed as a subcomponent a response against TERT. Nonetheless, the tumor-specific CTLs were consistently superior to the CTLs stimulated with TERT RNA-transfected DCs in recognizing and lysing tumor targets, suggesting that tumor-specific CTLs represent a polyclonal response providing more effective antitumor activity than T-cell responses directed against a single antigen in the form of TERT. Tumor RNA-transfected DCs were capable of stimulating T-cell reactivities not only against the primary tumor but also against metastatic tumors, although discrete differences in the antigenic repertoire expressed by these tissues were apparent. Thus, total tumor RNA-transfected DCs may represent a broadly applicable vaccine strategy to induce polyclonal and potentially therapeutic T-cell responses in renal cancer patients.

Antigens↗
PubMed2001

An antigen capture assay for the measurement of serum clusterin concentrations.

We have developed and validated a robust antigen capture assay for the measurement of serum clusterin. Increased clusterin expression, and alterations in serum clusterin levels have been associated with a number of disease states. In particular, clusterin has been shown to be associated with tissue regression and apoptosis in the rat ventral prostate in response to androgen ablation or administration of anti-androgens. The object of this study was to determine if changes in human serum clusterin can be used as a diagnostic or prognostic marker to monitor the response to hormonal therapy in patients with prostate cancer, and to determine if clusterin concentrations increase with the progression towards androgen independence. The antigen capture assay was used for an extensive analysis of human serum clusterin concentration in fasting males, and to determine if there is any relationship between clusterin and age or cholesterol levels. The average clusterin level in serum is 101+/-42 microg/ml (n=96). There is no correlation to age or serum cholesterol levels. Analysis of serum clusterin levels in patients with newly diagnosed prostate cancer (n=5), hormone responsive tumors (n=5), and hormone refractory disease (n=5), demonstrates that no significant changes in serum clusterin levels accompany the progression of prostatic disease, or response to hormone therapy.

Antigens↗